human colon carcinoma cells (5) , and activation of the transcription factor NF-κB (6) (7) (8) .
Furthermore, the soluble form of Fas ligand (sFasL) shed from activated T cells can act directly as a chemoattractant for neutrophils (9) . Collectively, these observations indicate that Fas-mediated signaling is not limited to inducing cell death. However, the molecular events triggering Fasmediated signals distinct from apoptosis induction have not been clearly delineated.
FADD is not only an essential signaling mediator for Fas-transduced apoptosis, but it also can be involved in signals that promote proliferation of TCR-activated T cells, as shown by the absence of activation-induced T proliferation in FADD knockout mice (10) or transgenic mice expressing dominant negative FADD (11, 12) . Therefore, Fas-mediated signaling pathways not associated with apoptosis induction can be branched out from FADD. It has been suggested that cFLIP (Casper/CASH/I-FLICE/CLARP) controls Fas signaling pathways downstream of FADD (13) (14) (15) (16) (17) .
cFLIP is a caspase-8-like molecule that lacks catalytic activity and has been known to act as a caspase-8 inhibitor by competing for the binding to FADD (18, 19) . interacts with tumor necrosis factor (TNF)-associated factor 1 and 2 (TRAF1 and 2), leading to the activation of NF-κB and extracellular signal regulated kinase 1 and 2 (ERK1/2) (20) . This observation suggests that the switch from the Fas-induced apoptotic pathway to a non-apoptotic signaling pathway may be determined by the equilibrium between caspase-8 and its repressor cFLIP and their competition for binding to FADD. Changes in the dynamics of the molecules involved in the decision making step may be affected by additional signals such as TCR stimulation in this specific setting. In fact, the function of Fas in a given cell type is known to be influenced by a cellular factor(s) whose expression or activation is affected by other stimuli. This idea is supported by the fact that many cells resistant to Fas-induced apoptosis become sensitive in the presence of metabolic inhibitors such as cycloheximide (CHX) and actinomycin D. In more physiological conditions, sensitivity to Fas-mediated apoptosis was shown to be influenced by certain combinations of inflammatory cytokines such as TNF, interferon-γ or interleukin-1 (21) . In addition, the ability of Fas to activate NF-κB and subsequent gene induction can be observed under conditions in which de novo protein synthesis is blocked or the apoptotic pathway is inhibited by treatment with caspase inhibitors (22) .
In the present study, we used the human diploid fibloblast cell line GM6112 to characterize Fasmediated signals not associated with apoptosis induction and to define conditions that favor the generation of Fas-mediated non-apoptotic signaling pathways. We show that upon sFasL treatment, GM6112 cells responded by the activation of ERK1/2 in the absence of c-Jun N-terminal kinase (JNK) and p38 activation. Serum starvation sensitized fibroblasts to Fas-mediated NF-κB activation, which correlated with the down-regulation of FADD and caspase-8 expression levels without a change in cFLIP expression. Our findings support the notion that a change in the ratio of cFLIP and caspase-8 may be responsible for the divergence of Fas signaling from the apoptotic pathway to a non-apoptotic pathway. 
EXPERIMENTAL PROCEDURES

Cell culture and Reagents
Culture media were purchased from Life Technologies Inc. Normal human diploid fibroblasts GM6112 were purchased from Human Genetic Mutant Cell Repository, Camden, NJ 08103.
GM6112 cells were grown in DMEM supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mM glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin. Human embryonic kidney cell line HEK293 was maintained in DMEM supplemented with 10% FCS.
Recombinant soluble FasL (sFasL) used in this study was prepared from culture supernatant of CHO-K1-sFasL cells grown in serum-free medium (CHO-S-SFM II; Life Technology). The biological activity of sFasL has been previously described (23, 24) . In most experiments cells were treated with medium containing 10 % (vol/vol) of the sFasL prepararation, corresponding to a final sFasL concentration of 1-2 µg/ml. Yeast-derived recombinant human TNF-α was kindly supplied by Dr. H. H. Chung, Biotech Research Institute, LG Chem., Korea. Phorbol-12-myristate-13-acetate (PMA), cycloheximide and anisomycin were purchased from Sigma. PD098059 was purchased from Calbiochem. Rabbit polyclonal α-PY(ab-1) antibody reactive to phospho-tyrosine residues was obtained from Dr. J. Schlessinger at NYU Medical Center. The rabbit anti-phospho-ERK and anti-phospho-p38 MAPK antibodies were purchased from New England Biolabs. The anti-Fas monoclonal antibody CH11 and antibodies to cFLIP and caspase-8 were purchased from Pharmingen. Antibodies to FADD and α-tubulin were from Transduction Laboratories and Sigma, respectively.
A cytomegalovirus (CMV) promoter-driven luciferase reporter plasmid, pCMV-luciferase (25) was used for indirect assessment of cell viability. 
Western blot analysis
For immunoblot analysis of cellular MAP kinases, cells were washed with cold PBS, scraped and resuspended in a buffer consisting of 1% Nonidet P-40, 50 mM Hepes, pH 7.5, 100 mM NaCl, min incubation at 30°C, the reaction was terminated by adding 2x Laemmli sample buffer and boiling for 3 min. Samples were resolved on 12% SDS-PAGE gel and subjected to autoradiography.
Transfection and Luciferase Assays
Transfection was carried out by the CaPO 4 -DNA precipitation method using Hepes or N,N-bis [2- hydroxyethyl]-2-aminoethanesulfonic acid (BES) buffer as described elsewhere (27) . Details of the transfection protocols used in GM6112 and HEK293 cells are described in the legend of Figure 6 .
Transfectants were lysed in 0.15 ml of lysis buffer (Promega) and centrifuged at 10,000 x g for 5 min to remove cell debris. The resulting clear lysates were assayed for luciferase and β-galactosidase activity, and the values of the luciferase assay were normalized with respect to the values of the β-galactosidase assay for relative comparison of each transfection.
Preparation of Nuclear Extracts and Electrophoretic Mobility Shift Assays (EMSA)
GM6112 cells were treated with sFasL at the indicated times. Nuclear extracts were prepared as described by Dignam et al. (28) , quantitated by the Bradford assay (Bio-Rad) and stored at -70 °C.
The oligonucleotide probes for the EMSA corresponded to the NF-κB binding sites in the c-IAP2 
RESULTS
Fas stimulation leads to ERK1 and ERK2 activation in human fibroblasts without significant increase in JNK and p38 MAPK activities
The serum-free culture supernatant of CHO-K1 cells secreting recombinant soluble FasL (sFasL) was used as an agent for triggering Fas expressed on a human diploid fibroblast cell line, GM6112. The apoptosis-inducing activity of the sFasL preparation was previously confirmed in T cells (23, 24) . In experiments to test Fas sensitivity of GM6112 cells, we observed that even after 11 11 fibroblasts were exposed to TNF (10 ng/ml) for the same time. In addition, concomitantly with the increased phosphorylation of the 42-and 44-kDa proteins after sFasL treatment, a tyrosinephosphorylated band at the position of approximately 200-kDa was also detected (marked by asterisk in Fig. 1A ). The activation of the high molecular weight protein was sFasL-specific because TNF treatment did not lead to phosphorylation of this protein.
ERK1/2 activation after exposure of GM6112 cells to sFasL, anti-Fas antibody CH11 and TNF for 15 min was confirmed by Western analysis using an ERK antibody recognizing phosphorylated tyrosine 204 of p42 and p44 MAPK (Fig. 1B) . When GM6112 cells were preincubated with 50 µM of PD098059 for 2 h, an activation inhibitor of ERK1/2, the ERK1/2 phosphorylation by sFasL, CH11, or TNF was completely inhibited, indicating that signals leading to ERK1/2 activation are MEK1-and 2-dependent.
Next, we assayed for sFasL-induced p38 and JNK activation, since previous studies have shown a role of these kinases in the regulation of Fas-mediated apoptosis (29) (30) (31) . When the same lysates were examined for p38 MAPK activation by Western analysis with the anti-phospho-p38 MAPK antibody specific for phosphorylated tyrosine 182 of p38 MAPK, no phosphorylated p38 MAPK was detected in sFasL-treated lysates (middle panel in Fig. 1A ). JNK activity in the lysates was determined by phosphorylation of GST-c-Jun (1-79). Fig. 1A (bottom panel) shows that stimulation with sFasL did not result in JNK activation, while TNF treatment led to a strong activation of JNK.
Activation of ERK1/2 by sFasL is phorbol ester-sensitive protein kinase C (PKC)-independent
To analyze early signaling events coupled to ERK1/2 activation by sFasL, we examined the contribution of the phorbol ester-sensitive PKC isotypes to the sFasL-mediated ERK1/2 activation.
Confluent cultures of GM6112 cells were treated with a high concentration (200 ng/ml) of PMA for 12 12 naïve GM6112 cells with a low concentration (10 ng/ml) of PMA caused ERK1/2 activation. In cells pretreated with the high dose of PMA, further treatment of PMA did not lead to ERK1/2 activation, indicating desensitization of the PKC pathway. However, PKC desensitization did not influence the ability of sFasL, CH11 and TNF to activate ERK1/2. Therefore, PMA-sensitive PKC isoforms are not involved in the activation of ERK1/2 by sFasL. It is interesting to note that TNF, which is mitogenic for serum-starved GM6112 cells (data not shown), also activated ERK1/2 in a PMA-sensitive PKC-independent manner. These results suggest that sFasL and TNF may use a common pathway leading to ERK activation and that ERK activation by sFasL is not linked to the apoptosis signaling pathways. When confluent GM6112 cultures were serum-starved in medium containing 0.25% FCS for 4 days, the addition of sFasL alone clearly induced gene activation. As shown in Fig. 3B , sFasL alone 
sFasL treatment induces IL-6 and IL-8 gene expression in serum-starved fibroblasts
Sensitization of the gene inducing activity of sFasL by serum-starvation correlates with its NF-κB inducing activity
Induction of IL-6 gene expression by various stimuli is primarily dependent on NF-κB activation (32) . Since our data demonstrated that in serum-starved cells, IL-6 gene can be activated by sFasL alone, we examined whether NF-κB is activated by sFasL under such conditions. We performed electrophoretic mobility shift assays (EMSA) with nuclear extracts of sFasL-treated cells that were either serum-starved or maintained in medium containing 10% FCS. As a probe, we used a NF-κB binding element from the promoter of the cellular inhibitor of apoptosis protein 2 (c-IAP2) gene (27) , because preliminary experiments consistently demonstrated higher NF-κB binding affinity than with the NF-κB site derived from the promoter of IL-6. As shown in Fig. 4 Since sFasL induced IL-6 gene expression when cells were serum-starved for at least 3 days, we examined the kinetics of the sFasL-induced NF-κB DNA binding activity in GM6112 cells maintained in serum-starved condition for various periods. As shown in Fig. 4 (right panel) , sFasLinduced NF-κB binding activity gradually increased as cells were serum-starved for 1, 2 or 4 days.
Competition assays using 100-fold or 300-fold excess of unlabeled c-IAP2 NF-κB or IL-6 NF-κB oligonucleotides, respectively, resulted in the disappearance of radioisotope-labeled bands, confirming the binding specificity of the nuclear proteins induced by sFasL.
Serum-starvation leads to the reduction of FADD and caspase-8 level in fibroblasts, while cFLIP level remains unchanged
To search for the mechanism that may be responsible for sensitizing NF-κB-dependent gene 
Down-regulation of caspase-8 level by expressing antisense caspase-8 RNA sensitizes cells to sFasL-induced NF-κB activation
To establish whether a causal relationship exists between the reduction of FADD and caspase-8 expression levels in serum-starved fibroblasts and the sensitization to NF-κB activation by sFasL, we down-regulated endogenous FADD or caspase-8 levels by the expression of their antisense RNAs, and examined sFasL-induced NF-κB-dependent reporter gene activation. As a reporter plasmid, we used an NF-κB-inducible luciferase construct comprising four copies of the IL-6 NF-κB binding site (pIL-6-kB-luc). As shown in in the nuclear extracts of serum-starved fibroblasts treated with sFasL, but not in the extracts of sFasL-treated cells maintained in serum-containing medium (Fig. 4) . The ability of Fas to activate NF-κB has been demonstrated in some cell lines (6) (7) (8) and in cortical neuroblast cultures derived from the developing mouse brain (37) . Moreover, as recently demonstrated by Wajant et al. (22), treatment of Fas-overexpressing HeLa cells with agonistic Fas antibody led to the induction of some genes whose activation is under the control of NF-κB. In our present experiments, NF-κB-dependent gene induction by sFasL was observed only in serum-starved GM6112 cells or when de novo protein synthesis was blocked by CHX, suggesting that one or more CHX-sensitive labile factors that also become depleted during serum starvation inhibit Fas-mediated NF-κB-dependent gene induction. In addition, treatment of CHX also sensitizes toward Fas-mediated apoptosis, as many cells resistant to Fas-mediated cell death become highly sensitive to Fas killing in the presence of CHX (1, 22) . Whether the same CHX-sensitive labile factor acts as an inhibitor for Fasactivated pathway leading to both cell death and NF-κB activation remains to be determined.
A previous report that overexpression of FADD not only induces cell death but also activates NF-κB (38) suggests that these two distinct Fas effects are likely to be regulated at the level of FADD. Upon Fas stimulation, a death-inducing signaling complex (DISC) comprising FADD and procaspase-8 is formed, and within DISC the recruited procaspase-8 is oligomerized and autocleaved to a mature enzyme. This active caspase-8 then provides the initiating signal in the caspase cascade. A known inhibitor of the Fas-activated death pathway, cFLIP has been suggested to control Fas-induced cell death by competing with caspase-8 for FADD (18, 19) . Several reports showed that up-regulation of cFLIP confers resistance to Fas-susceptible cells, and conversely down-regulation of cFLIP enhances Fas-mediated cell death (13, (39) (40) (41) . Therefore, cFLIP was proposed to act as a prime candidate for the short-lived regulatory factor whose expression is rapidly down-regulated by CHX treatment (22, 42) . carefully washed with medium to remove traces of glycerol and allowed to recover in fresh medium for 4 h. In order to minimize differences due to variations in transfection efficiency the cells were evenly split into 4 wells in a 6-well-dish. After incubation of the cells for 24 h in a 10% serumcontaining medium, two wells were left untreated and the other two were treated with sFasL for 8 h.
Cell lysates were prepared and processed for luciferase assays. The results shown are the average of three independent experiments, with each group run in duplicate. B, The experimental design was the same as for A, except that, instead of NF-κB luciferase plasmid, pCMV-luciferase reporter plasmid was used. After treating transfectants with sFasL for 24 h, cells were processed for luciferase assay. C, HEK293 cells were seeded into 12-well-dishes and grown to 70% confluence. by guest on October 1, 2017
